Renevil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renevil

Quick Facts

Property Description
Active ingredient Escitalopram (as Escitalopram oxalate)
Form Film-coated tablets, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulation of mood and emotional balance
Origin Synthetic compound

What Type of Medicine is Renevil?

Renevil is defined as a prescription-only psychotropic agent containing the active ingredient Escitalopram, and it is classified within the Selective Serotonin Reuptake Inhibitor (SSRI) pharmacological class. The medicine is primarily intended to modulate chemical messengers in the brain to support emotional stability, a function widely clinically recognized within established medical practice. Escitalopram is a serotonin reuptake inhibitor characterized by high specificity.

The core component, Escitalopram, represents a distinct structural refinement, as it is the highly selective S-enantiomer of the related compound Citalopram. This characteristic is a key differentiating factor, enabling a focused physiological action principally directed at the serotonergic system in the Central Nervous System (CNS). This targeted mechanism supports its use in scenarios such as managing persistent low mood, aligning with its role as a modern antidepressant.

Escitalopram: Composition and Form

Renevil is a single-ingredient product (monotherapy), with the active component being Escitalopram oxalate, a synthetic compound manufactured for precise oral delivery. It is characteristically supplied in two main dosage forms: the solid film-coated tablets and the liquid oral solution, facilitating the oral route of administration necessary for systemic effect.

The highly selective composition allows the compound to prevent the reuptake of the neurotransmitter serotonin by neurons. The formulation ensures sustained serotonergic activity, which serves the general therapeutic purpose of helping to establish a balanced and consistent emotional baseline. This focused chemical approach, differentiating it from older, less selective agents, forms the basis of its efficacy in supporting mood health.

What side effects are possible with Renevil?

Possible Side Effects and Safety Information for Renevil

The safety profile of Renevil is formally documented by governmental regulatory agencies, categorizing adverse reactions based on system-organ class and frequency.

Common and Uncommon Adverse Reactions

Adverse reactions that are frequently observed in clinical trials and post-marketing surveillance are typically categorized as Common (≥1/100 to <1/10) or Uncommon (≥1/1,000 to <1/100) in treated patients.

The most commonly affected System-Organ Classes (SOCs) are Gastrointestinal disorders (e.g., nausea, vomiting, diarrhea, constipation) and Nervous system disorders (e.g., headache, dizziness). Gastrointestinal events are frequently reported and can lead to discontinuation of therapy in a minority of patients.

Serious Adverse Reactions and Safety Restrictions

Regulatory warnings emphasize the potential for serious gastrointestinal adverse events, including reports of bowel obstruction, severe constipation, and, in rare instances, ulceration or perforation of the bowel. These events may necessitate hospitalization or surgical intervention.

Contraindications include patients with a known history of bowel obstruction or hypersensitivity to the active substance or its excipients. Caution is required in patients with pre-existing gastrointestinal motility disorders.

Population-Specific and Monitoring Notes

Specific safety considerations are noted for patients with severe underlying hepatic or renal impairment. Some adverse reactions may be dose-dependent, where the frequency or severity is observed to increase with higher drug exposure.

Official regulatory labeling includes requirements for appropriate monitoring of laboratory parameters and other clinical factors, particularly regarding potential drug-drug interactions that could alter the overall risk profile of the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Renevil (Escitalopram) may present with several documented clinical manifestations affecting multiple physiological systems. These commonly include central nervous system effects such as dizziness, somnolence, and tremor, alongside gastrointestinal disturbances like nausea and vomiting. Cardiovascular signs, specifically sinus tachycardia (rapid heart rate) and hypotension, have also been documented in overdose cases as defined in regulatory labeling.

Overdose exposure carries the risk of severe, life-threatening systemic outcomes. These include the potential for generalized seizures, coma, and the development of Serotonin Syndrome. Furthermore, official labeling notes dangerous cardiac complications, such as specific ECG changes like QTc prolongation and, rarely, ventricular arrhythmia. The severity of an overdose may be significantly increased when co-ingested with alcohol or other medicinal products.

Due to the potential for serious complications, regulators mandate that any suspected Renevil overdose requires that individuals seek immediate medical attention. This includes contacting a Poison Control Center or local emergency services. Management is focused on supportive and symptomatic treatment, as no specific antidote is known. Hospital-level care, including continuous cardiac and vital sign monitoring, is required following significant exposure, and activated charcoal may be considered.

Therapeutic Uses of Renevil

What Renevil Treats: Main Uses and Benefits

Renevil (Escitalopram) is generally considered relevant in the therapeutic domains of Affective Disorders and Anxiety Disorders to support appropriate symptomatic management. It is applied when distressing symptoms significantly interfere with daily stability and overall quality of life.

The medicine is commonly used to help manage the core symptoms of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). It may also be applied to address symptom patterns of episodic manifestations of intense fear, Social Anxiety Disorder, and Obsessive-Compulsive Disorder (OCD), which involve acute fear or intrusive thought patterns.

Supporting Emotional Balance and Symptom Relief

This medication plays a role in managing a variety of symptom clusters, including sustained sadness and the loss of interest or pleasure (anhedonia), excessive worry, and physical tension. Renevil is often used across acute episodes and for maintenance treatment.

“The therapeutic benefit supports the patient during difficult episodes by easing distress and may assist with managing the intensity of sudden, intense manifestations.”

The support provided may assist with managing the intensity of these distressing symptoms, and may contribute to improved day-to-day comfort during periods of heightened symptoms.


Quick Fact: Support for Excessive Worry and Loss of Interest The medication is relevant for addressing persistent emotional disturbances and generalized anxiety, and is used for managing symptoms of low mood and physical tension.

Eligibility and Restrictions for Use

Renevil’s population eligibility is strictly defined by government regulatory documents. Use is established for adults with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). For adolescents ge 12 years, use is established for MDD, and for children ge 7 years, use is established for GAD; however, safety and effectiveness are not established for these conditions in pediatric patients below those age thresholds.

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to escitalopram or citalopram. Absolute exclusion is also mandated for patients with known QT interval prolongation or congenital long QT syndrome. Additionally, co-administration is prohibited with Monoamine Oxidase Inhibitors (MAOIs), the antibiotic Linezolid, intravenous Methylene Blue, and the antipsychotic Pimozide.

Use of Renevil is conditional for specific populations. Older adults (ge 65 years) and patients with hepatic impairment are typically restricted to a lower maximum daily intake. Conditional use with caution is also required for individuals with severe renal impairment, a history of seizures, or conditions associated with a risk of hyponatremia or angle-closure glaucoma. Use during pregnancy and lactation is permitted only if the regulatory-defined potential benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Renevil (Escitalopram) as stated in government regulatory labels.


Contraindicated Combinations

The co-administration of Renevil is contraindicated with certain medicines due to the risk of severe adverse outcomes:

  • Monoamine Oxidase Inhibitors (MAOIs): Prohibited due to the significant risk of Serotonin Syndrome.
  • Pimozide and other medicinal products known to prolong the QT interval: Contraindicated due to the established risk of cardiac conduction changes.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agents / Classes Official Outcome Description
Metabolic (Pharmacokinetic) CYP2D6 Substrates (e.g., Desipramine, Metoprolol) Escitalopram inhibits CYP2D6, resulting in a documented doubling of exposure (100% increase in AUC) for co-administered substrates.
CYP2C19/CYP3A4 Inhibitors (e.g., Cimetidine, Omeprazole) May cause a significant, documented increase in Escitalopram plasma concentration (exposure).
Additive (Pharmacodynamic) Other Serotonergic Drugs (e.g., Triptans, Tramadol, Lithium, St. John’s Wort) Increased risk of Serotonin Syndrome.
Drugs Affecting Hemostasis (e.g., NSAIDs, Warfarin) Increased risk of abnormal bleeding.

Timing and Population Notes

A mandatory separation window requires that Escitalopram must not be used within 14 days of stopping an MAOI, and vice versa. Increased Escitalopram exposure is also officially noted in individuals classified as CYP2C19 Poor Metabolizers.

Mechanism of Action

How Renevil Works: Mechanism of Action


Selective Inhibition of Serotonin Reuptake

Renevil acts as a selective reuptake inhibitor by binding to the Serotonin Transporter (SERT) protein on pre-synaptic nerve cells. By inhibiting this transporter, the drug prevents the immediate reabsorption of the neurotransmitter serotonin (5-HT) back into the neuron. This molecular action leads to an increased concentration and duration of 5-HT signaling within the synaptic cleft, establishing the chemical basis for subsequent cellular adaptation.


Cellular Adaptation and Limbic System Modulation

The sustained elevation of serotonin triggers a time-dependent cellular cascade involving the down-regulation of inhibitory autoreceptors (e.g., 5-mathrmHT1mathrmA). This adaptation removes a key feedback mechanism that initially restricts serotonin release, resulting in a sustained increase in serotonergic neurotransmission. This process promotes neuroplasticity and modulates signaling within the Limbic System.


Mechanism Limitations and Time Dependency

The full functional outcome of this mechanism is dependent on the slower cellular changes, which explains the delay in the drug’s physiological effect. The mechanism is highly specific to the serotonergic system and may be constrained by individual genetic variations in the SERT protein itself, which can limit the transporter's availability or density.

Dosage and Administration Information

How to Use Renevil: Official Administration Guidelines

The administration of Renevil (Escitalopram) is defined by established guidelines, establishing a standard protocol for its use in clinical practice. The medicine is designated for oral administration and is available as film-coated tablets in strengths of 5 mg, 10 mg, and 20 mg, as well as an oral solution (1 mg/mL). The official frequency for all patient groups is once daily, and the dose can be taken with or without food.


Standard Dosing and Administration Schedule

Instruction Detail
Route of Administration Oral
Standard Adult Dose (MDD/GAD) Initial: 10 mg once daily. Maximum: 20 mg once daily.
Dose Escalation Timing Minimum of one week between dose increases (in adults).
Intake Flexibility Can be administered with or without food.
Handling (Solution) The oral solution must be shaken well before measuring.

Population-Specific Use and Cessation

Specific dosage limits are in place for certain populations, defining the upper procedural boundary for treatment. For older adults (65 years and over) and patients with hepatic impairment, the recommended dose ceiling is 10 mg once daily. Adolescents may require a minimum of three weeks at the starting dose before considering an increase. When therapy is concluded, the official procedural requirement is a gradual dose reduction (tapering) rather than abrupt cessation, which is a required component of the overall treatment structure. The overall duration of use is generally sustained, necessitating periodic reassessment for continued maintenance treatment.

Recent Clinical Evidence

Renevil: Recent Clinical Evidence

Research has demonstrated research interest in Renevil's potential efficacy and examined a reduction in moderate-to-severe pain. Studies also examined improved quality of life for patients. The scope of research focuses on how the medication affects pain management in various contexts.


Study 1: Efficacy in Chronic Pain

Clinical trials evaluated the drug's effect in patients experiencing chronic pain. The study reported lower average daily pain scores when participants receiving Renevil were compared to those receiving placebo. This measurement involved reviewing changes in pain scores over a short duration of treatment. Researchers also evaluated changes in reported pain within the first week of treatment.


Study 2: Combination Therapy

A secondary study examined the combination of Renevil with a standard non-opioid analgesic. The results indicated that participants using the combination reported differences in pain management scores compared to those receiving the standard analgesic alone. This study focused specifically on the combination therapy approach, which was evaluated in the context of overall treatment success and pain scores.

Frequently Asked Questions (FAQ)

Common questions about Renevil (FAQ)


Q: How is Renevil different from other similar phosphate binder drugs?

A: Official information states that Escitalopram (Renevil) is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Its established purpose is to modulate chemical messengers in the brain to support emotional balance. This is a very different function from phosphate binders, which are medicines designed to work in the gut to reduce the absorption of phosphate from food.

Q: How soon after starting Renevil can a person expect to see changes in lab results?

A: According to regulatory documents, the concentration of Escitalopram in the plasma reaches a consistent level (steady state) in the body within approximately one week of once-daily dosing. However, the full physiological outcome, which depends on slower changes in the brain's cells, typically takes several weeks of continuous treatment to develop.

Q: Does Renevil affect my body's absorption of vitamins?

A: Regulatory information indicates that the absorption of Escitalopram itself is not altered by food intake. While some medicines, vitamins, and herbal supplements may interact, official documents note that a healthcare provider can assess potential interactions.

Q: What is the typical time frame for follow-up bloodwork when starting Renevil?

A: The official labeling emphasizes that bloodwork and clinical factors should be monitored. While a fixed schedule is not dictated, regulatory guidance requires periodic re-evaluation by a healthcare provider to determine the drug's long-term appropriateness.

Q: Can Renevil be used by pregnant or breastfeeding individuals?

A: Use during pregnancy and breastfeeding is permitted only when the potential benefit is determined to justify the potential risk, as noted in regulatory documents. Low levels of the drug have been indicated in breast milk, and regulatory information suggests that infants be monitored for potential adverse effects.

Q: Does Renevil affect the absorption of birth control pills?

A: Official drug interaction information suggests that Escitalopram does not appear to directly alter the necessary concentrations of hormonal contraceptives. Therefore, the effectiveness of hormonal birth control is not noted to be typically impacted by the medicine, according to official interaction data.

Q: What should I do if I forget to take a dose of Renevil?

A: According to official patient information sheets, if a dose of Escitalopram is missed, it should be taken as soon as it is remembered. If it is closer to the next scheduled dose, the regulatory guidance is to omit the missed dose. Official information states that the dose should not be doubled to compensate for a missed dose.

Q: Is Renevil safe to use for children, and what are the age guidelines?

A: The medicine has established use for Major Depressive Disorder in adolescents aged 12 to 17 years. It is also established for Generalized Anxiety Disorder (GAD) in pediatric patients aged 7 years and older. Safety and effectiveness are not established by regulatory bodies for use in pediatric patients below those specific age thresholds.

Q: Does Renevil interact with common heart or blood pressure medications?

A: Official warnings state that Escitalopram is contraindicated (prohibited) with other medicines known to prolong the QT interval due to the risk of cardiac conduction changes. It is also required to be used with caution in individuals with pre-existing heart conditions because of the potential for cardiovascular effects.

Q: Can I take Renevil with juice or coffee instead of water?

A: The medicine is approved for administration with or without food. The official guidance does not restrict the use of non-interacting liquids. Any major interaction with specific beverages would be noted in the regulatory warnings.

Q: What is the generic name for Renevil?

A: The active ingredient in Renevil is Escitalopram (as Escitalopram oxalate). Escitalopram is the generic name for this prescription medicine.

Q: How does the powder form of Renevil need to be prepared before taking it?

A: The available liquid formulation is an oral solution, not a powder that requires mixing or reconstitution. The official regulatory guidance notes that the oral solution should be shaken well before the dose is measured.

Q: What happens if a person suddenly stops taking Renevil?

A: Abrupt cessation of Escitalopram should be avoided, as noted in official documents, because it may result in documented withdrawal symptoms. These symptoms can include dizziness, headache, nausea, tingling sensations, vomiting, or increased irritability. Regulatory guidance requires a gradual dose reduction (tapering) when discontinuing the medicine.

Q: Is Renevil known to interact with herbal supplements?

A: Regulatory sources state that Escitalopram is contraindicated (prohibited) with the herbal supplement St. John’s Wort due to a significant increase in the risk of Serotonin Syndrome. Official documents advise consulting a healthcare professional regarding all herbal remedies or supplements to understand potential interactions.

How should Renevil be stored and disposed of?

Official Storage Requirements

Renevil (Escitalopram) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). Temperatures may briefly deviate from 15°C to 30°C (59°F to 86°F).

The medicine should be kept in its original container with the bottle tightly closed to protect it from moisture and excessive heat. The oral solution formulation must be specifically protected from freezing.

Stability and Child Safety

For the oral solution, the product must be used within two months after it is first opened, as defined by its in-use stability period. All forms of the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Renevil should be disposed of through a dedicated drug take-back program or an authorized collector. The product is not recommended for disposal by flushing; it must not be poured down the drain or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Renevil found in:

A-Z Index: